For general health and antioxidant support, studies have shown that doses of between 250mg and 1000mg are effective
The participants who used semaglutide also saw greater improvements in their cardiometabolic health compared to those who only received the placebo
Baekdal TA, Breitschaft A, Navarria A, Hansen CW
Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, ODonnell H, et al
Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study
These effects have been demonstrated through in vitro studies, preclinical models, and clinical observations